GB9801398D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9801398D0
GB9801398D0 GBGB9801398.0A GB9801398A GB9801398D0 GB 9801398 D0 GB9801398 D0 GB 9801398D0 GB 9801398 A GB9801398 A GB 9801398A GB 9801398 D0 GB9801398 D0 GB 9801398D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
donor
independently selected
alkyl groups
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9801398.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANGGARD ERIK E
Original Assignee
ANGGARD ERIK E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANGGARD ERIK E filed Critical ANGGARD ERIK E
Priority to GBGB9801398.0A priority Critical patent/GB9801398D0/en
Publication of GB9801398D0 publication Critical patent/GB9801398D0/en
Priority to US09/600,711 priority patent/US6448267B1/en
Priority to PCT/GB1999/000231 priority patent/WO1999037616A1/en
Priority to AT99945671T priority patent/ATE277012T1/de
Priority to CA002318208A priority patent/CA2318208C/en
Priority to AU41206/99A priority patent/AU4120699A/en
Priority to JP2000528540A priority patent/JP2002501049A/ja
Priority to EP99945671A priority patent/EP1124801B1/en
Priority to DE69920496T priority patent/DE69920496T2/de
Priority to US10/093,251 priority patent/US6455542B1/en
Priority to US10/205,997 priority patent/US6759430B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB9801398.0A 1998-01-22 1998-01-22 Chemical compounds Ceased GB9801398D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds
DE69920496T DE69920496T2 (de) 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
CA002318208A CA2318208C (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
PCT/GB1999/000231 WO1999037616A1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
AT99945671T ATE277012T1 (de) 1998-01-22 1999-01-22 Piperidin- und pyrrolidin-derivate enthaltend ein stickstoffoxid donor zur behandlung von stress
US09/600,711 US6448267B1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
AU41206/99A AU4120699A (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
JP2000528540A JP2002501049A (ja) 1998-01-22 1999-01-22 ストレス処置のための一酸化窒素ドナーを含有するピペリジンおよびピロリジン誘導体
EP99945671A EP1124801B1 (en) 1998-01-22 1999-01-22 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
US10/093,251 US6455542B1 (en) 1998-01-22 2002-03-06 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
US10/205,997 US6759430B2 (en) 1998-01-22 2002-07-25 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9801398.0A GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9801398D0 true GB9801398D0 (en) 1998-03-18

Family

ID=10825732

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9801398.0A Ceased GB9801398D0 (en) 1998-01-22 1998-01-22 Chemical compounds

Country Status (9)

Country Link
US (3) US6448267B1 (enExample)
EP (1) EP1124801B1 (enExample)
JP (1) JP2002501049A (enExample)
AT (1) ATE277012T1 (enExample)
AU (1) AU4120699A (enExample)
CA (1) CA2318208C (enExample)
DE (1) DE69920496T2 (enExample)
GB (1) GB9801398D0 (enExample)
WO (1) WO1999037616A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
CN1370044A (zh) * 1999-06-14 2002-09-18 亨利福特保健系统公司 用于诱导神经发生的氧化氮供体
KR20010038797A (ko) * 1999-10-27 2001-05-15 김길환 홍국을 이용한 일산화질소 생성제 조성물 및 이를 이용한 약품 조성물
SE9903985D0 (sv) * 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
SG148838A1 (en) * 2000-08-22 2009-01-29 Boehringer Ingelheim Pharma Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20020151431A1 (en) * 2001-01-26 2002-10-17 Jeff Thornton Recovery method
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
CN100358515C (zh) * 2001-12-10 2008-01-02 杜燕生 神经退行性及心血管疾病之治疗药物
ATE310514T1 (de) 2002-04-19 2005-12-15 Yissum Res Dev Co Beta-agonisten-verbindungen mit stickoxid- donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
EP1578413A2 (en) * 2002-11-29 2005-09-28 Yissum Research Development Company of The Hebrew University of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
EP1603556A2 (en) * 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
CA2556967A1 (en) * 2004-02-23 2005-09-09 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP5630942B2 (ja) 2004-04-19 2014-11-26 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 不利な生物物理学的環境によりもたらされる有益な物質の経皮送達
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005118810A1 (en) 2004-06-03 2005-12-15 Athlomics Pty Ltd Agents and methods for diagnosing stress
WO2006020912A2 (en) * 2004-08-11 2006-02-23 The Regents Of The University Of California Treatments for congestive heart failure
WO2006037050A2 (en) * 2004-09-24 2006-04-06 Metaphore Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20090062338A1 (en) * 2005-02-02 2009-03-05 Louis Habash Nitroxides for use in treating or preventing cardiovascular disease
WO2006084041A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing diabetes
EP1858525A2 (en) * 2005-02-16 2007-11-28 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US20090215838A1 (en) * 2005-03-09 2009-08-27 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2606565C (en) 2005-05-27 2016-05-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2007024501A2 (en) 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
EP1968584A2 (en) * 2005-12-20 2008-09-17 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
US20080293702A1 (en) * 2005-12-22 2008-11-27 Nitromed, Inc. Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
BRPI0621639A2 (pt) * 2006-05-11 2011-12-20 Bell Helicopter Textron Inc dispositivo e método para reparo de componentes estruturais
WO2008048714A2 (en) * 2006-05-12 2008-04-24 Massachusetts Institute Of Technology Biradical polarizing agents for dynamic nuclear polarization
WO2007134160A2 (en) * 2006-05-12 2007-11-22 Massachusetts Institute Of Technology Temperature-jump dynamic nuclear polarization
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
JP5191702B2 (ja) * 2006-08-01 2013-05-08 三菱レイヨン株式会社 Ｎ−オキシル化合物、その製造方法および重合防止方法
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
DK2418945T3 (en) 2009-04-15 2019-02-25 Bmg Pharma S P A Mineral salt-sulfonic acid compositions and methods of use
CA2766354C (en) 2009-06-24 2019-08-13 Strategic Science & Technologies, Llc Topical compositions containing ibuprofen or sildenafil
US9072659B2 (en) 2009-06-24 2015-07-07 Strategic Science & Technologies, Llc Topical composition containing naproxen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
DK2467173T3 (da) 2009-08-21 2019-07-29 Novan Inc Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
CA2771308C (en) 2009-08-21 2020-01-21 Novan, Inc. Topical gels comprising nitric oxide releasing polysiloxane macromolecules
WO2011092690A1 (en) 2010-01-26 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Compositions and methods for prevention and treatment of pulmonary hypertension
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
WO2012093383A1 (en) 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
WO2013005216A1 (en) 2011-07-05 2013-01-10 Radikal Therapeutics Inc. Compositions and methods for treatment of renal ischemia-reperfusion injury
US8715621B2 (en) 2012-03-15 2014-05-06 Massachusetts Institute Of Technology Radical polarizing agents for dynamic nuclear polarization
WO2013190497A2 (en) 2012-06-21 2013-12-27 Radikal Therapeutics Inc. Compositions and methods for treatment of inflammatory diseases of the lung
AU2014224249B2 (en) 2013-03-05 2017-10-05 Salzman Group Pty. Ltd Prodrugs of multifunctional nitroxide derivatives and uses thereof
US10441568B2 (en) * 2015-03-26 2019-10-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nitroxide radicals for the treatment of diseases of the respiratory tract
CA3204594A1 (en) 2020-12-15 2022-06-23 Life Technologies Corporation Chemically defined serum albumin substitutes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3752812A (en) 1970-02-05 1973-08-14 Pfizer 2-trifluoromethylquinoxalinedi n oxides
US4563446A (en) 1983-07-27 1986-01-07 Takeda Chemical Industries, Ltd. Thromboxane synthetase inhibiting 3-(1-alkenyl) pyridines
DE3328365A1 (de) * 1983-08-03 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Neue diagnostische mittel
US5352442A (en) 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US5890387A (en) 1989-08-24 1999-04-06 Aquaform Inc. Apparatus and method for forming and hydropiercing a tubular frame member
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5700947A (en) 1993-10-06 1997-12-23 Nicox S.A. Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO1995030641A1 (en) 1994-05-10 1995-11-16 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
IT1276071B1 (it) 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US6140309A (en) 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5885842A (en) 1996-11-08 1999-03-23 Medinox, Inc. Methods for the detection of nitric oxide in fluid media
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
JP3377731B2 (ja) * 1997-09-29 2003-02-17 三菱重工業株式会社 高性能水素分離膜
AU2662799A (en) 1998-02-13 1999-08-30 Medinox, Inc. Modified pharmacologically active agents and improved therapeutic methods employing same
IN188837B (enExample) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
US6265420B1 (en) 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
AU775388B2 (en) 1998-11-25 2004-07-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scavenger compounds
IL143726A0 (en) 1998-12-14 2002-04-21 Cellegy Pharma Inc A pharmaceutical composition containing a nitric oxide donor
GB2349385A (en) 1999-04-30 2000-11-01 Teijin Ltd Organic nitrates and nitrites useful against heart disease
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
AU781084B2 (en) 1999-07-28 2005-05-05 Board Of Trustees Of The Leland Stanford Junior University Nicotine in therapeutic angiogenesis and vasculogenesis
SE9903985D0 (sv) 1999-11-03 1999-11-03 Aga Ab Use of nitric oxide

Also Published As

Publication number Publication date
CA2318208A1 (en) 1999-07-29
EP1124801A1 (en) 2001-08-22
DE69920496D1 (de) 2004-10-28
US6759430B2 (en) 2004-07-06
ATE277012T1 (de) 2004-10-15
JP2002501049A (ja) 2002-01-15
US20020091266A1 (en) 2002-07-11
EP1124801B1 (en) 2004-09-22
US6448267B1 (en) 2002-09-10
WO1999037616A1 (en) 1999-07-29
AU4120699A (en) 1999-08-09
US20030069429A1 (en) 2003-04-10
US6455542B1 (en) 2002-09-24
CA2318208C (en) 2009-09-29
DE69920496T2 (de) 2005-08-25

Similar Documents

Publication Publication Date Title
GB9801398D0 (en) Chemical compounds
CO5031285A1 (es) Triarilimidazoles
TR199901191T2 (xx) Benzamidoaldehitlerin sistein proteaz� inhibit�r� olarak kullan�m�.
AU6645998A (en) Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
IL126610A0 (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
MY119820A (en) Guanidine mimics as factor xa inhibitors
DE69529101D1 (de) Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
MXPA02000973A (es) Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
CA2421880A1 (en) Resorcinol derivatives
PL353337A1 (en) Substituted thiene-3-yl-sulfonyl amino(thio)carbonyl-triazolin(thi)ones
UA35574C2 (uk) Похідні заміщеної гетероциклом фенілциклогексанкарбонової кислоти, суміші їх ізомерів або окремі ізомери та їх солі
IL104567A0 (en) Ethanolamine derivatives,processes for the preparation thereof and a pharmaceutical composition containing the same
AU2001285807A1 (en) Acidic treatment liquid and method of treating copper surfaces
FI963978A0 (fi) Solususpensioiden preparointi ja stabilointi
MX9604483A (es) Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
DK0722319T3 (da) Anthracyclinonderivater samt deres anvendelse ved amyloidose
DK0882726T3 (da) Carbazolcarboxamider som 5-HT1F-agonister
ATE297903T1 (de) Substituierte phenyluracile
MX9702203A (es) Derivados de pirazolil-pirazol substituidos, procedimientos para su preparacion y su uso como agentes con accion herbicida.
WO1999003817A3 (en) Aliphatic propargylamines as cellular rescue agents
ES2000908A6 (es) Procedimiento para la fabricacion de nuevos derivados de alquilmercaptofenil-1,3,4-oxadiazol
IL135634A0 (en) 5-htif agonists
ES8802499A1 (es) Procedimiento para la obtencion de 1-aril-4-nitropirazoles
SE9904128D0 (sv) Novel compounds
PT89935A (pt) Processo para a preparacao de novos compostos cefem

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)